Jamie I. Fletcher

This study identifies venetoclax-alisertib as a promising combination therapy for high-risk neuroblastoma, particularly effective in MYCN-amplified models, with improved survival and reduced toxicity.

The paper identifies JNK-independent drugs that, when combined with standard chemotherapy, improve response in relapsed high-risk neuroblastoma by exploiting differential apoptotic network utilization.

This paper develops patient-derived tumour models using engineered ECM hydrogels to enable precision medicine for paediatric cancers by retaining tumour genotype and phenotype.